Effects of Statin Therapy on Inflammatory Markers in Chronic Heart Failure: A Meta-analysis of Randomized Controlled Trials

Archives of Medical Research

Volumn 41, Issue 6, 2010, Pages 464-471

  Zhang, Lei ^a   Zhang, Shuning ^a   Jiang, Hong ^a   Sun, Aijun ^a   Wang, Yunkai ^a   Zou, Yunzeng ^a,b   Ge, Junbo ^a,b   Chen, Haozhu ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Chronic heart failure; Inflammatory marker; Meta analysis; Statins

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CALCULATION; CLINICAL TRIAL; DATA EXTRACTION; EMBASE; FOLLOW UP; GENETIC HETEROGENEITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; MEDLINE; META ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78049422987     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.08.009     Document Type: Article

References (41)

1. Belch J.J., Bridges A.B., Scott N., et al. Oxygen free radicals and congestive heart failure. Br Heart J 1991, 65:245-248.
2. Ank er S.D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470.
3. Torre-Amione G. The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Curr Opin Cardiol 1999, 14:193-195.
4. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?. Circulation 1995, 92:1379-1382.
5. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353:1838-1842.
6. Kaneko K., Kanda T., Yamauchi Y., et al. C-reactive protein in dilated cardiomyopathy. Cardiology 1999, 91:215-219.
7. Devaux B., Scholz D., Hirche A., et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997, 18:470-479.
8. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000, 101:207-213.
9. Lefer D.J. Statins as potent antiinflammatory drugs. Circulation 2002, 106:2041-2042.
10. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
11. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
12. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
13. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006, 47:338-341.
14. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
15. Gissi- H.F., Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
16. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007, 13:1-7.
17. Laufs U., Wassmann S., Schackmann S., et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 2004, 93:103-108.
18. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47:332-337.
19. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005, 7:1126-1132.
20. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005, 178:359-363.
21. Wojnicz R., Wilczek K., Nowalany-Kozielska E., et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006, 97:899-904.
22. Yamada T., Node K., Mine T., et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007, 153:e1-e8.
23. Mann D.L. Mechanisms and models in heart failure-a combinatorial approach. Circulation 1999, 100:999-1008.
24. Adamopoulos S., Parissis J.T., Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001, 3:517-526.
25. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
26. Pinsky D.J., Cai B., Yang X., et al. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995, 95:677-685.
27. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
28. Yin W.H., Chen J.W., Jen H.L., et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004, 147:931-938.
29. Pedersen T.R., Kjekshus J., Berg K., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004, 5:81-87.
30. Takemoto M., Node K., Nakagami H., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001, 108:1429-1437.
31. Feron O., Dessy C., Desager J.P., et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
32. Drexler H., Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999, 31:51-60.
33. Nakagami H., Jensen K.S., Liao J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003, 35:398-403.
34. Lipinski M.J., Cauthen C.A., Biondi-Zoccai G.G., et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009, 104:1708-1716.
35. Hurks R., Hoefer I.E., Vink A., et al. Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. Eur J Vasc Endovasc Surg 2010, 39:569-576.
36. Kaya C., Pabuccu R., Cengiz S.D., et al. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 2010, 118:161-166.
37. Li J., Li J.J., He J.G., et al. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc Ther 2010, 28:8-14.
38. Jafarzadeh A., Esmaeeli-Nadimi A., Shariati M. High sensitivity C-reactive protein and immunoglobulin G against Chlamydia pneumoniae and chlamydial heat shock protein-60 in ischemic heart disease. Iran J Immunol 2008, 5:51-56.
39. Takeda T., Hoshida S., Nishino M., et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003, 169:155-158.
40. Berthonneche C., Sulpice T., Tanguy S., et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 2005, 19:251-259.
41. Tatli E., Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 2005, 21:344-348.